For the Treatment of Advanced Renal Cell Carcinoma, the Highest Proportion of Surveyed MCOs Select Pfizer's Sutent as the

However, Owing to Its Cost, Surveyed Oncologists and Payers Are Dissatisfied with Sutent’s Accessibility, According to Market Analysis from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of advanced renal cell carcinoma (RCC), the highest proportion of surveyed managed care organizations' (MCO) pharmacy directors select Pfizer's Sutent as the most efficacious and the safest and most tolerable agent.

The findings from Decision Resources’ analysis of the RCC drug market reveal that although surveyed oncologists and payers are satisfied with Sutent’s overall clinical profile, they are dissatisfied with the drug’s accessibility attributes.

“Surveyed oncologists who identified Sutent as having the best overall clinical profile assigned low satisfaction scores to the drug’s out-of-pocket costs and its overall cost,” said Decision Resources Analyst Ramya Kollipara, Ph.D. “Although it is covered by many insurance companies, Sutent is not available generically and appears on the second tier of many MCO formularies.”

The findings also reveal that surveyed U.S. oncologists and MCO pharmacy directors indicate that reducing the incidence of serious adverse events is one of the greatest unmet needs in advanced RCC. Clinical data and the opinions of interviewed thought leaders indicate that Aveo Pharmaceuticals’ emerging agent tivozanib has demonstrated the potential to fulfill this unmet need.

However, tivozanib will have to compete for patient share with several targeted agents—such as Sutent, GlaxoSmithKline’s Votrient/Patorma, and Pfizer’s emerging agent axitinib—which will already be available for treatment of advanced RCC when tivozanib is expected to launch for the indication in 2013. As a result, from 2013 to 2019, tivozanib is expected to garner modest peak-year sales of $100 million to $250 million for the treatment of advanced RCC.

Decision Resources’ Robust Opportunities and Forecast Market Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust opportunities and forecast market analysis is comprised of the Pharmacor 2011 advisory service and the DecisionBase 2011 report series.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Other Health  Research  Science  General Health  Managed Care